Cahill Represents Initial Purchasers in $1 Billion Notes Offering by Valeant Pharmaceuticals
Date: 01/30/15
Cahill represented Barclays Capital as lead book-running manager and the co-managers in connection with the Rule 144A offering of $1,000,000,000 aggregate principal amount of 5.5% Senior Notes due 2023 by Valeant Pharmaceuticals International, Inc. Proceeds from the offering will be used to refinance existing indebtedness and for general corporate purposes.